Colin Hill

Colin Hill is the president, chairman and co-founder of GNS Healthcare. He brings years of hands-on scientific experience to his role, with expertise in the areas of computational physics and systems biology.

Colin is a frequent speaker at international scientific and industry conferences and has appeared in numerous publications and television segments including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist. He serves as CEO and Chairman of GNS Healthcare’s parent company Via Science, and chairman of the board of Fina Technologies, a subsidiary of Via Science that applies next-generation artificial intelligence technology to real-time financial trading. He also serves on the board of directors of AesRx, a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease.

In 2004, Colin was named to MIT Technology Review’s TR100 list of the top innovators in the world under the age of 35. He graduated from Virginia Tech with a degree in physics and earned master’s degrees in physics from McGill University and Cornell University.

Radar